Endologix (ELGX) Downgraded to “Strong Sell” at ValuEngine

ValuEngine downgraded shares of Endologix (NASDAQ:ELGX) from a sell rating to a strong sell rating in a report published on Thursday.

A number of other equities analysts also recently issued reports on ELGX. BidaskClub downgraded Endologix from a hold rating to a sell rating in a report on Friday, January 19th. Zacks Investment Research downgraded Endologix from a hold rating to a sell rating in a report on Tuesday, January 30th. Finally, Oppenheimer set a $5.00 price objective on Endologix and gave the stock a hold rating in a report on Thursday, February 22nd. Two analysts have rated the stock with a sell rating, five have given a hold rating and two have assigned a buy rating to the company. Endologix has an average rating of Hold and a consensus target price of $5.05.

Shares of ELGX stock opened at $4.96 on Thursday. Endologix has a 52 week low of $3.75 and a 52 week high of $6.50. The firm has a market capitalization of $416.69 million, a P/E ratio of -10.33 and a beta of 0.32. The company has a quick ratio of 1.37, a current ratio of 2.13 and a debt-to-equity ratio of 3.58.

Endologix (NASDAQ:ELGX) last announced its quarterly earnings results on Wednesday, May 2nd. The medical instruments supplier reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.03. Endologix had a negative return on equity of 47.01% and a negative net margin of 35.86%. The company had revenue of $42.28 million during the quarter, compared to analyst estimates of $41.14 million. During the same quarter last year, the firm posted ($0.18) earnings per share. The firm’s revenue was down .8% on a year-over-year basis. sell-side analysts anticipate that Endologix will post -0.7 EPS for the current fiscal year.

Institutional investors and hedge funds have recently bought and sold shares of the business. Lake Street Advisors Group LLC bought a new position in Endologix in the fourth quarter worth $120,000. Quantitative Systematic Strategies LLC bought a new position in Endologix in the fourth quarter worth $139,000. Teacher Retirement System of Texas bought a new position in Endologix in the fourth quarter worth $144,000. MetLife Investment Advisors LLC bought a new position in Endologix in the fourth quarter worth $236,000. Finally, Millrace Asset Group Inc. bought a new position in Endologix in the fourth quarter worth $669,000.

About Endologix

Endologix, Inc develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. It offers minimally-invasive endovascular repair (EVAR) products, including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the ovation abdominal stent graft system.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Endologix (NASDAQ:ELGX)

Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.




Leave a Reply